Site Editor

David S. Ettinger, MD, FACP, FCCP

Advertisement

Advertisement

News

SITC 2022: Is Immunotherapy Feasible for Patients Living With HIV and NSCLC?

News

SITC 2022: First-Line Antigen Presenting Cell Activator Plus Pembrolizumab Under Study in NSCLC

News

SITC 2022: Can ctDNA Help to Predict Therapeutic Outcomes in Patients With NSCLC?

News

FDA Approves Combination Immunotherapy Regimen Plus Chemotherapy for Metastatic Lung Cancer

News

Can Weight Gain Improve Clinical Outcomes for Patients With Advanced NSCLC?

Medical Literature

Research on the Biologic Mechanism Underlying Acquired Osimertinib Resistance in NSCLC

News

Impact of Low-Dose CT Screening on Lung Cancer Incidence and Stage Migration

Stephanie T. Schmidt, PhD, on Neoadjuvant Chemotherapy and Immune-Based Treatments in NSCLC

Benjamin Besse, MD, PhD: Expert Insights Into a Neoepitope Vaccine for NSCLC

View More

Advertisement

JNCCN Spotlights

Dabrafenib + Trametinib (Tafinlar + Mekinist)

Crizotinib (Xalkori)

(UPDATE) Pembrolizumab (Keytruda) in NSCLC

(UPDATE) Nivolumab (Opdivo) in NSCLC

(UPDATE) Afatinib (Gilotrif)

Sotorasib

View More

More

News

Can a Liquid Biomarker Augment Early Screening for Lung Cancer?

Molecular Profiling of Patients With Progressive NSCLC After Osimertinib Treatment

ASTRO 2022: Phase III Trial Compares Radiotherapy Regimens for Early-Stage NSCLC

Impact of Low-Dose CT Screening on Lung Cancer Incidence and Stage Migration

Overall Survival Analysis From Phase III JIPANG Trial in Nonsquamous Lung Cancer

ESMO 2022: 5-Year Update From KEYNOTE-189 on Pembrolizumab Plus Chemotherapy in NSCLC

SITC 2022: Is Immunotherapy Feasible for Patients Living With HIV and NSCLC?

FDA Grants Regular Approval to Selpercatinib in Locally Advanced or Metastatic RET Fusion–Positive NSCLC

View More

Advertisement

Published

Medical Literature

Adjuvant Atezolizumab Versus Best Supportive Care in Resected Early-Stage NSCLC: IMpower010 Results

Use of Nintedanib/Docetaxel in Advanced Nonsquamous Lung Cancer: Phase III Trial Results

Update From ALTER-L004: First-Line Anlotinib Plus Icotinib in EGFR-Mutated NSCLC

Does Bias Affect Overall Survival Reporting in ALK-Positive NSCLC Treated With Alectinib Versus Ceritinib?

View More

Ongoing

CE Activities

Tailoring Targeted Therapy: New Directions for Managing Patients Across the Spectrum of Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer: Management of Patients With Resectable Disease

KRAS Mutations in NSCLC: Who, How, and When to Test

Meet The Professor: Current and Future Role of Immunotherapy in the Management of Lung Cancer — Part 1 of a 4-Part Series

View More

Available

Clinical Trials

The University of Texas MD Anderson Cancer Center, NORTHSTAR Trial

Fox Chase Cancer Center

City of Hope Comprehensive Cancer Center

A Randomized Phase II Trial of Adjuvant Pembrolizumab for Stage I Non-Small Cell Lung Cancer with Primary Tumors Between 1-4 cm

View More

Resources

For Your Patients

The American Lung Association

Bonnie J. Addario Lung Cancer Foundation

Caring Ambassadors Program

Dusty Joy Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2022 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.